The challenge of emerging SARS-CoV-2 mutants to vaccine development

doi:10.1016/j.jgg.2021.03.001

Review

. 2021 Feb 20;48(2):102-106.

doi: 10.1016/j.jgg.2021.03.001. Epub 2021 Apr 20.

The challenge of emerging SARS-CoV-2 mutants to vaccine development

Rong Li¹, Jun Liu¹, Hui Zhang²

Affiliations

¹ Institute of Human Virology, Key Laboratory of Tropical Disease Control of Ministry of Education, Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong 510080, China.
² Institute of Human Virology, Key Laboratory of Tropical Disease Control of Ministry of Education, Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong 510080, China. Electronic address: zhangh92@mail.sysu.edu.cn.

PMID: 33994322
PMCID: PMC8056881
DOI: 10.1016/j.jgg.2021.03.001

Review

The challenge of emerging SARS-CoV-2 mutants to vaccine development

Rong Li et al. J Genet Genomics. 2021.

. 2021 Feb 20;48(2):102-106.

doi: 10.1016/j.jgg.2021.03.001. Epub 2021 Apr 20.

Authors

Rong Li¹, Jun Liu¹, Hui Zhang²

Affiliations

¹ Institute of Human Virology, Key Laboratory of Tropical Disease Control of Ministry of Education, Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong 510080, China.
² Institute of Human Virology, Key Laboratory of Tropical Disease Control of Ministry of Education, Guangdong Engineering Research Center for Antimicrobial Agent and Immunotechnology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, Guangdong 510080, China. Electronic address: zhangh92@mail.sysu.edu.cn.

PMID: 33994322
PMCID: PMC8056881
DOI: 10.1016/j.jgg.2021.03.001

No abstract available

PubMed Disclaimer

Figures

**Fig. 1**
Mutations in several notable SARS-CoV-2 variants. Schematic of the full-length spike protein of SARS-CoV-2 variants, including G614, D614, B.1.1.7, 501Y.V2, and P.1 lineage. Mutations in the spike protein of these different variants are shown in yellow labeled with the precise position. NTD, N terminal domain; RBD, receptor-binding domain; FP, fusion peptide; HR1, heptad repeat 1; HR2, heptad repeat 2; TM, transmembrane domain.

See this image and copyright information in PMC

Cited by

ACE2-based capacitance sensor for rapid native SARS-CoV-2 detection in biological fluids and its correlation with real-time PCR.
Georgas A, Lampas E, Houhoula DP, Skoufias A, Patsilinakos S, Tsafaridis I, Patrinos GP, Adamopoulos N, Ferraro A, Hristoforou E. Georgas A, et al. Biosens Bioelectron. 2022 Apr 15;202:114021. doi: 10.1016/j.bios.2022.114021. Epub 2022 Jan 21. Biosens Bioelectron. 2022. PMID: 35092924 Free PMC article.
In vitro induction of interleukin-8 by SARS-CoV-2 Spike protein is inhibited in bronchial epithelial IB3-1 cells by a miR-93-5p agomiR.
Gasparello J, d'Aversa E, Breveglieri G, Borgatti M, Finotti A, Gambari R. Gasparello J, et al. Int Immunopharmacol. 2021 Dec;101(Pt B):108201. doi: 10.1016/j.intimp.2021.108201. Epub 2021 Sep 28. Int Immunopharmacol. 2021. PMID: 34653729 Free PMC article.
Surface charge changes in spike RBD mutations of SARS-CoV-2 and its variant strains alter the virus evasiveness via HSPGs: A review and mechanistic hypothesis.
Zhang Z, Zhang J, Wang J. Zhang Z, et al. Front Public Health. 2022 Aug 24;10:952916. doi: 10.3389/fpubh.2022.952916. eCollection 2022. Front Public Health. 2022. PMID: 36091499 Free PMC article. Review.
A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2.
Yuan Y, Zhang X, Chen R, Li Y, Wu B, Li R, Zou F, Ma X, Wang X, Chen Q, Deng J, Zhang Y, Chen T, Lin Y, Yan S, Zhang X, Li C, Bu X, Peng Y, Ke C, Deng K, Pan T, He X, Zhang Y, Zhang H. Yuan Y, et al. Cell Rep. 2022 Jan 18;38(3):110256. doi: 10.1016/j.celrep.2021.110256. Epub 2021 Dec 23. Cell Rep. 2022. PMID: 34990583 Free PMC article.
Impact of Vaccination on Intra-Host Genetic Diversity of Patients Infected with SARS-CoV-2 Gamma Lineage.
Marques BC, Banho CA, Sacchetto L, Negri A, Vasilakis N, Nogueira ML. Marques BC, et al. Viruses. 2024 Sep 26;16(10):1524. doi: 10.3390/v16101524. Viruses. 2024. PMID: 39459859 Free PMC article.

See all "Cited by" articles

References

1. Buss L.F., Prete C.A., Abrahim C.M.M., Mendrone A., Salomon T., de Almeida-Neto C., França R.F.O., Belotti M.C., Carvalho M.P.S.S., Costa A.G., et al. Three-quarters attack rate of SARS-CoV-2 in the Brazilian amazon during a largely unmitigated epidemic. Science. 2021;371:288–292. - PMC - PubMed
1. Chen R.E., Zhang X., Case J.B., Winkler E.S., Liu Y., VanBlargan L.A., Liu J., Errico J.M., Xie X., Suryadevara N., et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 2021;27:717–726. - PMC - PubMed
1. Collier D.A., De Marco A., Ferreira I.A., Meng B., Datir R., Walls A.C., Kemp S.S.A., Bassi J., Pinto D.,, Fregni C.S., et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature. 2021;593:136–141. - PMC - PubMed
1. Edara V.V., Floyd K., Lai L., Gardner M., Hudson W., Piantadosi A., Waggoner J.J., Babiker A., Ahmed R., Xie X., et al. Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant. medRxiv. 2021 doi: 10.1101/2021.02.02.21250799. - DOI
1. Eguia R., Crawford K.H.D., Stevens-Ayers T., Kelnhofer-Millevolte L., Greninger A.L., Englund J.A., Boeckh M.J., Bloom J.D. A human coronavirus evolves antigenically to escape antibody immunity. PLoS Pathog. 2021;17:e1009453. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations
Medical
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] Buss L.F., Prete C.A., Abrahim C.M.M., Mendrone A., Salomon T., de Almeida-Neto C., França R.F.O., Belotti M.C., Carvalho M.P.S.S., Costa A.G., et al. Three-quarters attack rate of SARS-CoV-2 in the Brazilian amazon during a largely unmitigated epidemic. Science. 2021;371:288–292. - PMC - PubMed

[2] Buss L.F., Prete C.A., Abrahim C.M.M., Mendrone A., Salomon T., de Almeida-Neto C., França R.F.O., Belotti M.C., Carvalho M.P.S.S., Costa A.G., et al. Three-quarters attack rate of SARS-CoV-2 in the Brazilian amazon during a largely unmitigated epidemic. Science. 2021;371:288–292. - PMC - PubMed

[3] Chen R.E., Zhang X., Case J.B., Winkler E.S., Liu Y., VanBlargan L.A., Liu J., Errico J.M., Xie X., Suryadevara N., et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 2021;27:717–726. - PMC - PubMed

[4] Chen R.E., Zhang X., Case J.B., Winkler E.S., Liu Y., VanBlargan L.A., Liu J., Errico J.M., Xie X., Suryadevara N., et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat. Med. 2021;27:717–726. - PMC - PubMed

[5] Collier D.A., De Marco A., Ferreira I.A., Meng B., Datir R., Walls A.C., Kemp S.S.A., Bassi J., Pinto D.,, Fregni C.S., et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature. 2021;593:136–141. - PMC - PubMed

[6] Collier D.A., De Marco A., Ferreira I.A., Meng B., Datir R., Walls A.C., Kemp S.S.A., Bassi J., Pinto D.,, Fregni C.S., et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies. Nature. 2021;593:136–141. - PMC - PubMed

[7] Edara V.V., Floyd K., Lai L., Gardner M., Hudson W., Piantadosi A., Waggoner J.J., Babiker A., Ahmed R., Xie X., et al. Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant. medRxiv. 2021 doi: 10.1101/2021.02.02.21250799. - DOI

[8] Edara V.V., Floyd K., Lai L., Gardner M., Hudson W., Piantadosi A., Waggoner J.J., Babiker A., Ahmed R., Xie X., et al. Infection and mRNA-1273 vaccine antibodies neutralize SARS-CoV-2 UK variant. medRxiv. 2021 doi: 10.1101/2021.02.02.21250799. - DOI

[9] Eguia R., Crawford K.H.D., Stevens-Ayers T., Kelnhofer-Millevolte L., Greninger A.L., Englund J.A., Boeckh M.J., Bloom J.D. A human coronavirus evolves antigenically to escape antibody immunity. PLoS Pathog. 2021;17:e1009453. - PMC - PubMed

[10] Eguia R., Crawford K.H.D., Stevens-Ayers T., Kelnhofer-Millevolte L., Greninger A.L., Englund J.A., Boeckh M.J., Bloom J.D. A human coronavirus evolves antigenically to escape antibody immunity. PLoS Pathog. 2021;17:e1009453. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

The challenge of emerging SARS-CoV-2 mutants to vaccine development

Affiliations

The challenge of emerging SARS-CoV-2 mutants to vaccine development

Authors

Affiliations

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous

Figures

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Miscellaneous